High dose of d-chiro-inositol improves oocyte quality in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial.
Nicolás Mendoza Ladrón de GuevaraMaria Isabel GalanCristina MolinaRaquel Mendoza-TesarikCristina CondeMaryna MazheikaMaria Paz Diaz-RoperoJuristo FonollaJan TesarikMonica OlivaresPublished in: Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology (2019)
The aim of this study was to evaluate the effect of two doses of d-chiro-inositol (DCI) in combination with Myo-inositol (MYO) on the oocyte quality (OQ) of women with polycystic ovarian syndrome (PCOS) undergoing intracytoplasmic sperm injection (ICSI). Methods: This was a controlled, randomized, double-blind, parallel group study on 172 oocytes from 11 women. The study compared the effect of two MYO-DCI formulations given over 12 weeks on OQ. Five women received 550 mg of MYO + 300 mg of DCI daily (high DCI content group), while 6 women were given a daily dose of 550 mg of MYO with the only 27.6 mg of DCI (low DCI content group). Results: According to a multivariate analysis using linear mixed effect models, high doses of DCI have a positive influence on the quality of the cytoplasm of the oocyte (β = 1.631, χ2 = 7.347, d.f. = 1, p = .00672). Zona pellucida, plasma membrane, cytoplasm, and sperm reception have also been improved with any combination of MYO/DCI by decreasing testosterone or improving insulin sensitivity, regardless of age and body mass index. Conclusion: The combination of MYO with high doses of DCI improved oocyte cytoplasm quality in women with PCOS undergoing ICSI.
Keyphrases
- polycystic ovary syndrome
- pregnancy outcomes
- double blind
- high dose
- body mass index
- insulin resistance
- physical activity
- placebo controlled
- cervical cancer screening
- quality improvement
- pregnant women
- clinical trial
- breast cancer risk
- low dose
- open label
- metabolic syndrome
- adipose tissue
- case report
- skeletal muscle
- ultrasound guided